SPSanjana Pannem

Sanjana Pannem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sanjana Pannem has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dual-channel pulse-dye densitometry can enable correction of fluorescent targeted and control agent plasma input function differences for quantitative paired-agent molecular imaging: a simulation study

    by Cody C. Rounds, Yichen Feng, Sanjana Pannem, Jovan Brankov, Kimberly S. Samkoe, Kenneth M. Tichauer

    In recent years, paired-agent imaging (PAI) strategies have been explored owing to their ability to yield quantitative in vivo imaging of cell-surface receptors.1 – 3 PAI requires the administration of at least two imaging agents of similar blood and tissue kinetics where one agent is targeted to a biomolecule of interest and one is untargeted (the “control” agent). By measuring the dynamics of the control agent, non-specific accumulation of the targeted agent and variable targeted agent delivery (attributable to the variability of blood flow and vascular permeability among tissues, particularly cancerous tissues) can potentially be accounted for, allowing for more quantitative estimates of the targeted agent’s specific binding through the approximation of a quantity termed the “binding potential” (BP). BP is directly proportional to the concentration of an agent’s biomolecular target,4 and as such, the measurement of this quantity can give critical insight into the disease state and phenotype of a biological tissue. In the context of surgical oncology, BP mapping (compared with targeted agent distribution mapping) may enable improved discrimination between malignant and non-malignant tissue types.5,6

  • Advancing Paired Agent Imaging for Head and Neck Cancer

    by Sanjana Pannem, Yichen Feng, Sassan Hodge, Eunice Chen, Jonathan Elliott, Kenneth Tichauer, Keith Paulsen, Kimberely Samkoe

    Paired Agent Imaging was tested in in vivo mouse models, demonstrating consistent binding potential (BP) quantification across increasing dosage, stable BP quantification at timepoints >5h, and no significant effects due to injection methodology.

  • Open Access

    Stealth Liposomes Encapsulating a Potent ACAT1/SOAT1 Inhibitor F12511: Pharmacokinetic, Biodistribution, and Toxicity Studies in Wild-Type Mice and Efficacy Studies in Triple Transgenic Alzheimer’s Disease Mice

    by Adrianna L. De La Torre, Thao N. Huynh, Catherine C. Y. Chang, Darcy B. Pooler, Dylan B. Ness, Lionel D. Lewis, Sanjana Pannem, Yichen Feng, Kimberley S. Samkoe, William F. Hickey, et al.

    Cholesterol is essential for cellular function and is stored as cholesteryl esters (CEs). CEs biosynthesis is catalyzed by the enzymes acyl-CoA:cholesterol acyltransferase 1 and 2 (ACAT1 and ACAT2), with ACAT1 being the primary isoenzyme in most cells in humans. In Alzheimer’s Disease, CEs accumulate in vulnerable brain regions. Therefore, ACATs may be promising targets for treating AD. F12511 is a high-affinity ACAT1 inhibitor that has passed phase 1 safety tests for antiatherosclerosis. Previously, we developed a nanoparticle system to encapsulate a large concentration of F12511 into a stealth liposome (DSPE-PEG2000 with phosphatidylcholine). Here, we injected the nanoparticle encapsulated F12511 (nanoparticle F) intravenously (IV) in wild-type mice and performed an HPLC/MS/MS analysis and ACAT enzyme activity measurement. The results demonstrated that F12511 was present within the mouse brain after a single IV but did not overaccumulate in the brain or other tissues after repeated IVs. A histological examination showed that F12511 did not cause overt neurological or systemic toxicity. We then showed that a 2-week IV delivery of nanoparticle F to aging 3xTg AD mice ameliorated amyloidopathy, reduced hyperphosphorylated tau and nonphosphorylated tau, and reduced neuroinflammation. This work lays the foundation for nanoparticle F to be used as a possible therapy for AD and other neurodegenerative diseases.